The ethics committee approved the mid-term report of the third phase of the Nanocovax vaccine

Avatar of Nick John By Nick John Dec21,2023 #committee #Nanocovax
The ethics committee approved the mid-term report of the third phase of the Nanocovax vaccine 3
The ethics committee approved the mid-term report of the third phase of the Nanocovax vaccine 3

Professor Truong Viet Dung, Chairman of the National Council of Ethics in Biomedical Research (referred to as the Ethics Council) confirmed the information with VnExpress on the evening of September 18 and said that the results `basically have been achieved.`

In order, the Nanocovax clinical trial research results continue to be sent to the Advisory Council for issuance of drug registration certificates and medicinal ingredients for consideration and emergency licensing.

This is the second time the Ethics Council has met to appraise the results of the third phase of the Nanocovax vaccine clinical trial.

Nanogen company employee holds Nanocovax sample in hand, at the laboratory in District 9;

Nanocovax is a Covid-19 vaccine researched and developed by Nanogen Company, a course of two doses administered 28 days apart.

Phase 1 study on 60 volunteers from 18 to 50 years old, including 3 dose levels of 25 mcg;

Phase 2 research on 560 volunteers aged 18 years and older, including 4 groups: 80 people injected with placebo;

On June 11, as soon as the results of the mid-term evaluation of phase 2 were available, the Ministry of Health approved the phase 3 clinical trial research outline, research period until February 2023, with the main goal

Phase three is divided into phase 3a and phase 3b, the research objective is to evaluate the safety, immunogenic response and protective efficacy of the Nanocovax candidate.

On September 10, the vaccine completed testing for volunteers in both phases.

Related Post

Leave a Reply

Your email address will not be published. Required fields are marked *